Patients
SCLC, allergic
BRAIN METASTASIS, SCLC, MALIGNANT TUMORS, ONCOLOGY, DISEASE PROGRESSION
In this single‐arm, phase II prospective study, pretreated patients with advanced SCLC were selected. The eligibility criteria were as follows: (1) 18–75‐years‐old; (2) Eastern Cooperative Oncology Group (ECOG) performance score ≤2; (3) Pathological examination confirmed SCLC; (4) Limited stage patients could receive thoracic radiation, surgery, or any other curative intent therapy as first‐line therapy; (5) Disease progression after first‐line chemotherapy; Platinum‐sensitive patients (relapse ≥6 months after first‐line chemotherapy) or platinum‐resistant patients (relapse <6 months after first‐line chemotherapy); (6) Absence of brain metastasis or asymptomatic brain metastasis was allowed; (7) Normal function of major organs (appropriate hematological, coagulation, hepatic, and renal function). The key exclusion criteria were as follows: (1) Previous treatment with apatinib or other antiangiogenetic agents; (2) Patients with other malignant tumors; (3) Patients allergic or intolerant to the study drugs.Generally, the first‐line therapy including surgery or radiotherapy refers to the initial treatment of patients with confirmed SCLC, we listed some conditions for the first‐line therapy including surgery or radiotherapy. (1) Some very early limited‐stage SCLC patients with clinical stage T1‐2N0M0 can undergo surgical treatment if the body can tolerate it, and then chemotherapy and radiotherapy should be further performed after the surgeryThis study was performed following the Declaration of Helsinki and the Principles of Good Clinical Practice. The protocol was reviewed and approved by the institutional review board of The First Hospital of Jilin University, Changchun, China and written informed consent was obtained from each participant. The 